SCHEMBL2763136

SCHEMBL2763136

CS(=O)(=O)c1nccc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(Cl)c2)n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 8/20 0.62
BRAF P15056 11/20 0.59
RAF1 P04049 8/20 0.57
MAPK3 P27361 2/20 0.55
RIPK2 O43353 2/20 0.55
ABCB11 O95342 2/20 0.55
ABL1 P00519 2/20 0.55
RET P07949 2/20 0.55
HTR1A P08908 2/20 0.55
PDGFRB P09619 2/20 0.55
ADORA3 P0DMS8 2/20 0.55
KIT P10721 2/20 0.55
FGFR1 P11362 2/20 0.55
PDGFRA P16234 2/20 0.55
FLT1 P17948 2/20 0.55
MAOA P21397 2/20 0.55
EPHA1 P21709 2/20 0.55
TBXA2R P21731 2/20 0.55
EPHA2 P29317 2/20 0.55
TTK P33981 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2763258 0.93 BRAF (0.65) KDRBRAFRAF1MAPK3RIPK2
SCHEMBL2762618 0.92 KDR (0.73) KDRBRAFRAF1MAPK3RIPK2
SCHEMBL2763200 0.85 KDR (0.63) KDRBRAFRAF1MAPK3RIPK2
SCHEMBL2762801 0.80 KDR (0.59) KDRBRAFRAF1MAPK3RIPK2
SCHEMBL2762560 0.79 BRAF (0.66) KDRBRAFRAF1MAPK3RIPK2
SCHEMBL13946001 0.78 RAF1 (0.65) KDRBRAFRAF1MAPK3RIPK2
SCHEMBL5086313 0.78 RAF1 (0.87) KDRBRAFRAF1MAPK3RIPK2
SCHEMBL4462580 0.77 BRAF (0.70) KDRBRAFRAF1
SCHEMBL2762668 0.77 KDR (0.73) KDRBRAFABL1RETEPHA2
SCHEMBL2763177 0.77 KDR (0.74) KDRBRAFRAF1MAPK3RIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8080552-B2 Pyrimidyl derivatives as protein kinase inhibitors HOFFMANN-LA ROCHE INC. (US) 2011-12-20 US disclosed
EP-2102173-B1 PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2010-10-20 EP disclosed
US-20100041684-A1 PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-02-18 US disclosed
EP-2102173-A1 PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS F. Hoffmann-Roche AG (CH) 2009-09-23 EP disclosed
WO-2008077548-A1 PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041684-A1 PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS MAP3K5, MAP3K1, MAP4K2 KDR 1270/4885BRAF 47/4885RAF1 210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.